{"denoms":[{"counts":[{"groupId":"BG000","value":"501"},{"groupId":"BG001","value":"496"},{"groupId":"BG002","value":"997"}],"units":"Participants"}],"groups":[{"description":"Participants received 200 mg of tislelizumab intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Thereafter, participants continued treatment with 200 mg tislelizumab, with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.","id":"BG000","title":"Tislelizumab + Chemotherapy"},{"description":"Participants received placebo intravenously with investigator's choice of chemotherapy once every 3 weeks for up to six treatment cycles. Thereafter, participants continued treatment with placebo with optional maintenance capecitabine (only permitted for participants who initially received capecitabine and oxaliplatin) once every 3 weeks until disease progression or unacceptable toxicity.","id":"BG001","title":"Placebo + Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"340"},{"groupId":"BG001","value":"313"},{"groupId":"BG002","value":"653"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"161"},{"groupId":"BG001","value":"183"},{"groupId":"BG002","value":"344"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.07","value":"58.8"},{"groupId":"BG001","spread":"11.20","value":"59.7"},{"groupId":"BG002","spread":"11.14","value":"59.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"305"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"346"},{"groupId":"BG001","value":"346"},{"groupId":"BG002","value":"692"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"492"},{"groupId":"BG001","value":"474"},{"groupId":"BG002","value":"966"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"23"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"376"},{"groupId":"BG001","value":"372"},{"groupId":"BG002","value":"748"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"223"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"24"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Unknown"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"259"},{"groupId":"BG001","value":"257"},{"groupId":"BG002","value":"516"}],"title":"China (including Taiwan)"},{"measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"232"}],"title":"Japan and South Korea"},{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"124"},{"groupId":"BG002","value":"249"}],"title":"North America/Europe"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"405"},{"groupId":"BG001","value":"395"},{"groupId":"BG002","value":"800"}],"title":"Stomach"},{"measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"196"}],"title":"Gastro-oesophageal junction"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Other*"}]}],"description":"\\*One participant in the placebo + chemotherapy arm did not report primary location and disease stage, as the diagnosis of this participant was updated from gastric adenocarcinoma to be pancreatic cancer after randomization.","paramType":"COUNT_OF_PARTICIPANTS","title":"Primary Tumor Location","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"224"},{"groupId":"BG002","value":"451"}],"title":"< 5%"},{"measurements":[{"groupId":"BG000","value":"274"},{"groupId":"BG001","value":"272"},{"groupId":"BG002","value":"546"}],"title":"≥ 5%"}]}],"description":"PDL1 expression was assessed by a central laboratory using the TAP score, defined as total percentage of tumor area (tumor and any desmoplastic stroma) covered by tumor cells with PD-L1 membrane staining (any intensity), and tumor associated immune cells with PD-L1 staining (any intensity), visually estimated by pathologists using an investigational use only version of the Ventana PDL1 (SP263) assay.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 Expression","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"220"},{"groupId":"BG001","value":"214"},{"groupId":"BG002","value":"434"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"281"},{"groupId":"BG001","value":"282"},{"groupId":"BG002","value":"563"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Presence of Peritoneal Metastasis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"466"},{"groupId":"BG001","value":"465"},{"groupId":"BG002","value":"931"}],"title":"Oxaliplatin + Capecitabine"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"66"}],"title":"Cisplatin + 5-Fluorouracil"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Investigator Chosen Chemotherapy","unitOfMeasure":"Participants"}]}